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Cystic fibrosis pathophysiology
Cystic  fibrosis  (CF)  is  a  recessive  disorder  caused  by 
muta  tions to the gene encoding the cystic fibrosis trans­
membrane  conductance  regulator  (CFTR),  a  chloride 
channel responsible for directing the movement of salt 
and water in and out of cells. To date, over 1,700 muta­
tions of this gene [1], categorized into six classes accord­
ing to their functional effects [2], have been linked to CF. 
F508del is the most common mutation and accounts for 
70% of CF in most Caucasian populations [3].
The reduction of CFTR activity perturbs normal water 
and salt balance, resulting in the production of unusually 
thick, sticky mucus at tissue surfaces. This reduction in 
surface  fluid  in  the  lung  promotes  persistent  and 
recurrent infections by impeding the mucociliary clear­
ance of invading microbes [4], and in the digestive tract 
by hindering the movement of feces, which may cause 
bowel  obstruction.  Mucus  plugging  in  the  glands  may 
block ducts, leading to tissue scarring and loss of func­
tion.  In  particular,  ductal  plugging  of  the  pancreas 
prevents the production of sufficient digestive enzymes 
for effective nutrition.
Protein targets in current CF clinical trials
Following the cloning of the CF gene in 1989 [5] and the 
subsequent  introduction  of  DNA­based  disease  diag­
nosis,  the  focus  of  protein  target  discovery  shifted 
towards the identification of candidate drug targets and 
indicators of disease severity and/or response to treat­
ment. Restoration of normal CFTR function is the chief 
therapeutic goal as this will address the underlying cause 
of CF disease rather than just treat the symptoms. Gene 
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CFTR genes to the epithelial cells of the CF airway. In 
phase  1,  treatment  with  aerosolized  compacted  DNA 
nano  particles  containing  the  CFTR  gene  (Copernicus 
Therapeutics,  Cleveland,  Ohio,  USA)  induced  nasal 
chloride  current  changes  in  CF  patients,  suggesting 
increased CFTR functionality, but gene expression was 
not detected [6]. The UK Cystic Fibrosis Gene Therapy 
Consortium [7] is currently performing a phase 1/2 safety 
study using pGM169/GL67A [8] and will proceed to a 
multidose study in July 2011. This system utilizes lipo­
somes  to  promote  the  aerosolized  delivery  of  a  DNA 
plasmid containing the CFTR gene.
Two  drugs  from  Vertex  Pharmaceuticals  (Abingdon, 
UK), VX­770 and VX­809, aiming to promote the activity 
of  mutant  CFTR  by  increasing  channel  opening  and 
trafficking to the membrane, respectively, are currently in 
clinical trials [6]. In phase 2, VX­770 improved measures 
of CFTR function such as nasal potential difference and 
sweat  chloride  concentration  [6].  Ataluren  (formerly 
PTC124; PTC Therapeutics, South Plainfield, New Jersey, 
USA),  which  is  designed  to  increase  synthesis  of  full­
length  functional  CFTR,  improved  CFTR  function  for 
some patients in phase 2 trials [9] and is currently in phase 
3 [6]. Sildenafil, which corrects F508del­CFTR traffick  ing 
and increased chloride transport in F508del­CFTR mice 
[10], is the subject of phase 1/2 clinical trials [8].
Lung  disease,  resulting  from  chronic  infection  and 
inflammation, is the most common cause of death in the 
CF population and thus its treatment is a key goal of CF 
therapy. In the CF lung, activation of the nuclear factor 
(NF)­κB signaling pathway leads to enhanced production 
of  pro­inflammatory  mediators,  including  interleukin 
(IL)­8. IL­8 is a potent neutrophil chemoattractant result­
ing in neutrophil recruitment and accompanying tissue 
damage through the release of neutrophil proteases and 
reactive  oxygen  species.  Drugs  are  being  developed  to 
treat  various  proteins  involved  in  this  inflammatory 
cycle.  Digitoxin  has  been  shown  to  suppress  hyper­
secretion of pro­inflammatory IL­8 by CF lung epithelial 
cells  in  vitro  [11]  and  its  effect  on  sputum  IL­8  and 
neutrophil counts is currently being assessed in a phase 2 
clinical trial (ClinicalTrials.gov Identifier: NCT00782288 
[8]). GSK SB 656933 (GlaxoSmithKline, Uxbridge, UK) is 
an  antagonist  of  the  neutrophil  IL­8  receptor  CXCR2, 
which  mediates  neutrophil  migration.  It  has  demon­
strated  safety  in  a  phase  1  trial  [6]  and  is  now  being 
evaluated in a phase 2 study (ClinicalTrials.gov Identifier: 
NCT00903201 [8]) for pharmacodynamics and efficacy, 
including  the  reduction  of  sputum  neutrophil  elastase 
and neutrophil counts. Pioglitazone, already approved for 
treatment of other clinical conditions, is being assessed 
for safety and anti­inflammatory action in phase 1 clinical 
trials against CF lung disease [6]. Its target, peroxisome 
proliferator­activated receptor γ, which is reduced in CF 
[12],  exerts  an  anti­inflammatory  effect  by  negatively 
regu  lat  ing NF­κB activation [13]. The sputum protease 
matrix metalloproteinase­9 has also been linked to poor 
lung function and airway inflammation in CF children 
[14]  and  its  activity  is  being  targeted  by  the  antibiotic 
doxycycline  in  a  current  trial  (ClinicalTrials.gov 
Identifier: NCT01112059 [8]).
Various proteins and protein degradation products have 
been  explored  as  candidate  biomarkers  of  clinical 
outcome, such as neutrophil elastase and IL­8 [15], degra­
dation  of  lung  surfactant  protein  SP­A  [16],  urinary 
desmosine [17] and proline­glycine­proline [18]. However, 
as yet, none of these markers has been proven sufficiently 
robust for routine adoption in clinical trials [19].
Proteomic contributions to CF research
Preclinical  medical  research  is  increasingly  adopting  a 
systems  rather  than  a  reductionist  approach  to  under­
standing  and  treating  disease,  with  clinical  proteomics 
contributing to the characterization and measurement of 
pathophysiological stages. Proteomic­based CF research 
has  employed  techniques  such  as  two­dimensional  gel 
electrophoresis  (2­DE),  liquid  chromatography,  mass 
spectrometry (MS) and antibody/protein microarrays to 
analyze secretions, cells and whole tissues from in vitro 
or in vivo disease models, human subjects and infecting 
micro­organisms.  Laser  capture  microdissection,  cell 
fractionation  and  co­immunoprecipitation  have  been 
used to limit analyses to the sub­proteomes of interest.
Global  comparative  analyses  of  CF  versus  non­CF 
samples  have  been  used  to  identify  differentially  ex­
pressed proteins in human bronchoalveolar lavage fluid 
(BALF) [20,21], sputum [22], bronchial biopsy tissue [23], 
serum [24] and cultured epithelial cells [25,26], and in 
mouse  lung  and  colonic  tissue  [27­29].  Many  of  the 
proteins  highlighted  by  global  analyses  can  be  related 
functionally to biological processes and pathways known 
to  contribute  to  CF  disease  pathogenesis,  including 
chronic inflammation, proteolytic activity and oxidative 
stress response proteins.
Chronic neutrophil­mediated inflammation typifies the 
CF  lung,  and  comparative  proteomic  studies  have 
provided data to support and improve our understanding 
of the mechanisms involved. Srivastava et al. [24] have 
detected  in  CF  serum  differential  levels  of  proteins 
belonging  to  the  NF­κB  pathway,  which  is  known  to 
enhance  production  of  inflammatory  mediators,  while 
Sloane et al. [30] have found that sputum from adults 
with CF is characterized by inflammation­related proteins, 
including  increased  production  of  IL­8.  Neutrophil 
proteins, including α­defensins and S100 proteins, have 
been shown to be differentially expressed in CF BALF [31] 
and sputum [22]. Also, lower levels of anti­inflammatory 
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[29] have been observed in CF nasal epithelial cells and 
sputum,  respectively.  Additionally,  the  absence  of 
annexin A1 has been associated with upregulation of the 
proinflammatory  cytosolic  phospholipase  A2  in  the 
colonic crypts of CF mice [29].
Chronic  inflammation  of  the  CF  lung  is  thought  to 
induce the overexpression of proteases, thus perturbing 
the protease/anti­protease balance and resulting in tissue 
damage and disease. Through the application of shotgun 
proteomic methods, Gharib et al. [20] detected increased 
levels of 22 proteases and peptidases in human CF BALF, 
including neutrophil elastase, cathepsin G and proteinase 
3.  They  also  identified  increased  expression  of  human 
monocyte/neutrophil elastase inhibitor [20], which when 
applied  as  an  aerosolized  treatment  to  rats  has  been 
shown to reduce inflammation [32]. Extensive proteolytic 
degradation, including truncation of the anti­protease α1­
antitrypsin and degradation of IgG, has been observed in 
CF sputum [30].
High  levels  of  toxic  reactive  oxygen  species  and 
oxidative stress are characteristic of the CF lung. Reduced 
glutathione, which acts as an antioxidant and in detoxifi­
cation,  has  been  observed  at  a  lower  level  in  CF  lung 
lavage fluid [33]. In support of this finding, Roxo­Rosa et 
al. [26] have detected, via 2­DE comparative proteomics 
of CF and non­CF mouse nasal epithelial cells, reductions 
in the levels of glutathione­related proteins: glutathione 
S­transferase, which catalyses the glutathione­mediated 
detoxification of oxidative stress products; peroxiredoxin 
6,  a  glutathione­dependent  peroxidase  involved  in 
defense against oxidative stress; and Hsp27, a heat shock 
protein  that  can  increase  intracellular  levels  of  gluta­
thione and acts as a chaperone for detoxification. Other 
proteomic studies have identified differential expression 
of myeloperoxidase, superoxide dismutase, catalase and 
glutathione  reductase  in  CF  BALF  [20],  and  increased 
levels of myeloperoxidase in CF sputum [30]. Together 
these data help elucidate mechanisms that are likely to 
contribute to oxidative stress in the CF lung.
Other  biological  processes  and  proteins  where  func­
tional  links  to  CF  disease  are  less  well  established  or 
absent have also been implicated by global comparative 
proteomics.  Differential  expression  of  mitochondrial 
proteins has been reported in human CF nasal epithelial 
cells  [26]  and  bronchial  tissue  [23],  implicating  a  CF­
associated reduction in mitochondrial metabolism, and 
the recent mapping of the CF BALF proteome [20] has 
implicated dysregulation of the complement system as a 
novel  CF  phenotype  that  may  impact  lung  disease 
pathogenesis by impairing response to chronic infections. 
Investigation of the response of murine CF airway epi­
thelial  cells  to  injury  detected  reductions  in  enzymes 
involved in prostaglandin and retinoic acid metabolism; 
this implicates these pathways in the CF abnormal injury 
response, although no functional role has been determined.
More  focused  comparative  proteomic  studies  have 
concentrated  on  specific  protein  subgroups,  such  as 
those  involved  in  pathways  of  interest  or  executing 
certain roles. An investigation by Chen et al. [34] of the 
mechanisms triggering the overproduction of cytokines 
IL­6  and  IL­8,  associated  with  excessive  CF  lung 
inflammation,  identified  a  regulatory  pathway  that  is 
significantly reduced in CF. Moreover, they demonstrated 
that  correction  of  the  pathway  reduced  IL­6  and  IL­8 
production  [34].  Individual  protein  families  have  also 
been  studied,  such  as  lung  surfactant  proteins  and 
mucins, both of which are involved in pathogen clearance 
from  the  airways.  The  structural  modification  of  lung 
surfactant proteins SP­A and SP­D [35] and degradation 
of  mucins  MUC5B  and  MUC5AC  [36]  have  been 
detected in CF BALF and sputum, respectively, and are 
thought  to  be  relevant  to  lung  disease.  Additionally, 
mucin glycosylation has been highlighted as a possible 
predictor of lung condition [36].
Particular  attention  has  been  directed  towards 
identifying  proteins  that  interact  with  CFTR  with  the 
goal  of  understanding  and  restoring  normal  CFTR 
proteostasis through the correction of CFTR synthesis, 
folding, aggregation, degradation, trafficking and stable 
localization. F508del, the most common mutation of the 
CFTR gene, gives rise to incorrectly folded CFTR that is 
translocated  from  the  endoplasmic  reticulum  to  the 
cytosol for proteosomal degradation. An investigation by 
Goldstein et al. [37] of proteins that co­precipitate with 
F508del­CFTR  has  identified  interaction  with  valosin­
containing protein (VCP)/p9, a component of the trans­
location machinery, as being associated with inefficient 
processing of the mutant CFTR. Gomes­Alves et al. [38] 
used  2­DE  to  compare  protein  profiles  of  cell  lines 
expressing wild­type or F508del­CFTR at 37°C and 26°C, 
and have identified mechanisms, including the induction 
of the unfolded protein response and downregulation of 
degradative proteins, which may contribute to the cold­
shock­induced  rescue  of  F508del­CFTR.  By  comparing 
the  CFTR  interactomes  of  bronchial  epithelial  cells 
expressing chemically and genetically repaired F508del­
CFTR, Singh et al. [39] identified a set of Hsp70 family 
proteins as implicated in rescue of the mutant protein. 
Additionally, Wang et al. [40] showed the importance of 
Hsp60 co­chaperones in CFTR folding and demonstrated 
rescue of F508del­CFTR by partial small interfering RNA 
silencing  of  the  Hsp60  co­chaperone  Aha1. 
Understanding  the  mechanisms  that  can  contri  bute  to 
F508del­CFTR rescue may suggest potential thera  peutic 
targets. Also, study of the CFTR interactome has led to 
elucidation of the molecular defect of S13F­CFTR [41] as 
relating  to  defective  interaction  with  filamins,  which 
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Repeated or chronic microbial infection is thought to 
be a major contributor to the excessive inflammation that 
precipitates CF lung damage, and a variety of proteomic 
approaches  have  been  exploited  to  discover  bacterial 
antigenic biomarkers that could provide potential candi­
dates  for  infection  diagnosis,  prognosis  indicators  or 
vaccine development. Pedersen et al. [42] used a novel 
enrichment technique employing CF patient antibodies 
as capture ligands prior to proteomic analysis to enhance 
the  identification  of  Pseudomonas  aeruginosa  antigens. 
The  antigens  detected  by  this  method  included  stress, 
immunosuppressive  and  alginate  synthetase  pathway 
proteins.  Using  proteomic  analysis  of  non­enriched 
serum samples from CF patients with different stages of 
infection,  Rao  et  al.  [43]  identified  outer  membrane 
protein  OprL  as  associated  with  initial  P.  aeruginosa 
infection and thus proposed serum reactivity to OprL as 
an early diagnostic. Montor et al. [44] generated protein 
microarrays displaying all predicted outer membrane and 
exported proteins expressed by P. aeruginosa reference 
strain PAO1 and used these to interrogate serum samples 
from CF patients infected with P. aeruginosa. They identi­
fied 48 antigenic proteins, 12 of which were common to 
approximately 50% of the samples. Alterna  tively, whole 
cell MS has been proposed for the rapid identification of 
commonly misidentified bacterial species [45].
Proteomics  has  helped  elucidate  factors  pertinent  to 
virulence, adaptation and in vivo survival of the pathogen 
P. aeruginosa [46­49], which is particularly indicative of a 
poor prognosis [50]. These may present candidate drug 
targets  for  treatment  of  CF  infections.  The  quorum 
sensing  intercellular  communication  systems  have 
received  particular  attention  as  they  largely  coordinate 
bacterial virulence [51,52].
The future potential of proteomics
The constant advance of proteomic strategies, instrumen­
tation and data analysis provides an ever­increasing set of 
tools available for expanding CF research. Two strands 
for future studies are envisaged: the continuing investi­
gation  of  disease  pathology  aiming  to  discover  prog­
nostic,  diagnostic  and  therapeutic  biomarkers;  and  the 
translation  of  existing  knowledge  into  clinical  appli­
cations of benefit to the CF population. The recent drift 
from traditional 2­DE to gel­free methods for protein and 
peptide separation is still under­represented in CF bio­
marker discovery, although their potential for extending 
shotgun (that is, global) proteome coverage has already 
been  demonstrated  for  BALF.  By  complementing 
traditional  gel  separation  of  proteins  with  the  two­
dimensional liquid chromatography separation of tryptic 
digests, Guo et al. [53] were able to improve the number 
of proteins detected in mouse BALF from 212 to 297, 
although they noted that their methods did not permit 
quantitative analyses. More recently, Gharib et al. [20] 
used quantitative shotgun proteomics to compare human 
CF and non­CF BALF from 12 subjects, and were able to 
distinguish  the  differential  expression  of  hundreds  of 
proteins, including those involved in pathways implicated 
in CF pathophysiology. Wider adoption of these approaches 
will enable protein detection over a larger dynamic range, 
thus  including  in  the  pool  of  potential  biomarkers 
proteins of lower abundance that could not be detected 
using traditional proteomic techniques. Future biomarker 
discovery  will  also  greatly  benefit  from  the  recent 
generation  of  pigs  with  mutated  CFTR  genes  [54,55], 
which  provides  a  model  that  more  closely  resembles 
human  disease  than  current  mouse  models,  and  thus 
enables  further  investigation  of  biomarkers  relevant  to 
long­term disease progression and treatment efficacy.
The major shortfall in current proteomics research is 
the gap between the discovery of biomarkers and their 
clinical application. One hindrance has been the lack of 
tools  for  high­throughput  validation.  Advances  in  MS 
selected reaction monitoring have enabled the concur­
rent  measurement  of  multiple  researcher­designated 
proteins in a sample and may in future bypass the need 
for the development of a separate antibody­based assay 
for each individual proteins to be quantified [56]. This 
increases the feasibility of assaying large sample numbers 
with sufficiently high specificity and sensitivity to enable 
the simultaneous statistical validation of multiple candi­
date biomarkers [57]. The validation of a panel of CF­
specific protein biomarkers could precipitate the produc­
tion  of  novel  biomarker  arrays  or  tests  for  individual 
proteins. Such tools would permit the quantification of 
new outcome measures for assessing disease progression 
and/or response to treatment in clinical trials, and may 
be applicable to future routine clinical practice [58].
Conclusions
Proteins  and  their  interactions  ultimately  steer  CF 
disease, making their study invaluable for improving our 
understanding  of  pathophysiology  and  potential  treat­
ment  opportunities.  Considerable  knowledge  has  been 
gained  so  far  by  the  application  of  proteomics  to  CF 
research  and  rapid  advancements  in  this  field  are 
expected  to  augment  its  future  contribution  towards 
improving the prognosis of CF patients.
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